HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Nov.24) - Gold Content Of License-Out Deals, NRDL Pricing Levels, CR Sanjiu

Sinocelltech Group (688520.CH) - Magical Leaps in Valuation Are Hard to Sustain

Dong E E Jiao Co Ltd (000423.CH) - The Situation Is Getting Better and Better

GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?

Innovent Biologics Placement (1801.HK) - There Is No Such Thing as a Free Lunch

China's Weight Loss Drug Market – The Investment Opportunities and the Risks Behind

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Innovent Biologics Inc / Equity Bottom-Up

<ul>
<li>After COVID-19, China healthcare has been under pressure for a long time. High interest rate environment is unfriendly to companies, but the current situation is not entirely devoid of opportunities.</li>
<li>GLP-1s has reignited investors’ interest in this industry, which will be long-term opportunity and bring alpha. With rich domestic/overseas catalysts ahead, related share price performance is worth looking forward to.</li>
<li>Among the domestic GLP-1s companies, Innovent is our top pick. The "concept validation" of Innovent’s business model has been completed. A qualitative change in the Company is coming soon.  </li>
</ul>


After COVID-19, China healthcare has been under pressure for a long time. High interest rate environment is unfriendly to companies, but the current situation is not entirely devoid of opportunities.
GLP-1s has reignited investors’ interest in this industry, which will be long-term opportunity and bring alpha. With rich domestic/overseas catalysts ahead, related share price performance is worth looking forward to.
Among the domestic GLP-1s companies, Innovent is our top pick. The "concept validation" of Innovent’s business model has been completed. A qualitative change in the Company is coming soon.  


2024 High Conviction – China Healthcare: It's Time to Embrace a New Era